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Human myeloma cell lines (HMCLs) and a subset of myeloma patients with poor prog-
nosis exhibit high levels of replication stress (RS), leading to DNA damage. In this study, 
we confirmed the presence of DNA double-strand breaks (DSBs) in several HMCLs 
by measuring γH2AX and RAD51 foci and analyzed the effect of various inhibitors of 
the DNA damage response on MM cell survival. Inhibition of ataxia telangiectasia and 
Rad3-related protein (ATR), the main kinase mediating the response to RS, using the 
specific inhibitor VE-821 induced more cell death in HMCLs than in control lympho-
blastoid cells and U266, an HMCL with a low level of DNA damage. The absence of 
ATR was partially compensated by ataxia telangiectasia-mutated protein (ATM), since 
chemical inhibition of both kinases using VE-821 and KU-55933 significantly increased 
the death of MM cells with DNA damage. We found that ATM and ATR are involved 
in DSB repair by homologous recombination (HR) in MM. Inhibition of both kinases 
resulted in a stronger inhibition that may underlie cell death induction, since abolition of 
HR using two different inhibitors severely reduced survival of HMCLs that exhibit DNA 
damage. On the other hand, inhibition of the other route involved in DSB repair, non- 
homologous end joining (NHEJ), using the DNA-PK inhibitor NU7441, did not affect MM 
cell viability. Interestingly, we found that NHEJ inhibition did not increase cell death when 
HR was simultaneously inhibited with the RAD51 inhibitor B02, but it clearly increased 
the level of cell death when HR was inhibited with the MRE11 inhibitor mirin, which 
interferes with recombination before DNA resection takes place. Taken together, our 
results demonstrate for the first time that MM cells with ongoing DNA damage rely on 
an intact HR pathway, which thereby suggests therapeutic opportunities. We also show 
that inhibition of HR after the initial step of end resection might be more appropriate 
for inducing MM cell death, since it prevents the occurrence of a compensatory NHEJ 
repair mechanism. These preclinical observations provide the rationale for its clinical 
evaluation.
Keywords: Dna damage response, Dna damage, ataxia telangiectasia-mutated protein, ataxia telangiectasia 
and rad3-related protein, double-strand break repair, homologous recombination, non-homologous end joining
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inTrODUcTiOn
Multiple myeloma (MM), the second most common hematologi-
cal malignancy, arises from the abnormal clonal proliferation of 
malignant plasma cells (1, 2). Current therapies have significantly 
improved survival of MM patients. On the one hand, high-dose 
melphalan followed by autologous hematopoietic cell transplant 
has become a standard of care for young patients after bortezomib-
based induction regimens. On the other hand, the introduction of 
novel agents, particularly bortezomib combined with alkylating 
drugs and prednisone, or lenalidomide plus dexamethasone has 
also improved the outcome of patients who are ineligible for 
high-dose therapy (3, 4). Nevertheless, MM remains an incur-
able disease, and new therapeutic strategies are still needed. A 
prominent feature of MM cells is their genome instability, whose 
underlying molecular basis is not fully understood. Recently, it 
has been proposed that high levels of ongoing intrinsic DNA 
damage and deregulated double-strand break (DSB) repair influ-
ence the acquisition of genomic changes (5–8).
Double-strand breaks pose a serious threat to cell viability 
and genome stability if left unrepaired or if they are repaired 
incorrectly (9). These DNA lesions can be generated exogenously, 
by exposure to a variety of genotoxic agents, or endogenously, 
due to various factors that slow down or stall replication forks, 
a phenomenon known as replication stress (RS). Sources of RS 
include fragile sites, replication–transcription complex collision, 
secondary DNA structures, and oncogenic stress (10, 11). To 
limit the impact of DSBs, cells have evolved the DNA damage 
response (DDR), a signal transduction cascade that coordinates 
the signaling and repair of these genomic lesions (9). Ataxia 
telangiectasia-mutated protein (ATM) and ataxia telangiectasia 
and Rad3-related protein (ATR) are central components of the 
DDR. ATM is a serine–threonine kinase that phosphorylates 
several key proteins, leading to cell cycle arrest through phospho-
rylation of CHK2, DNA repair, or apoptosis (12–14). It is mainly 
activated by DSBs, such as those induced by ionizing radiation 
(IR). In contrast, ATR is the key kinase in signaling the response 
to single-strand DNA (ssDNA), which can occur at persistent 
DSBs and on stalled replication forks. It is considered to be the 
main kinase mediating the response to RS (10).
Once DNA damage has been detected, DSBs are mainly 
repaired by two pathways: non-homologous end joining (NHEJ) 
and homologous recombination (HR). NHEJ is based on a direct 
ligation of the two ends of damaged DNA molecules and repairs 
DSBs mainly in G1 phase, although it is active throughout the cell 
cycle (15–17). HR promotes the recovery or repair of lesions that 
arise during replication and has a less important role in the repair 
of non-replication-associated DSBs (18). The pathway starts with 
the 5′-to-3′ resection of DNA ends, which is initiated by the 
endonuclease MRE11. The generated 3′-ssDNA overhangs bind 
to replication protein A, which is then exchanged for RAD51, the 
recombinase involved in the search for homology in the sister 
chromatid, thereby allowing subsequent repair (19).
High levels of RS leading to DNA damage have recently 
been described in a subset of MM (8). These patients, who 
overexpressed genes belonging to a chromosomal instability 
and DNA damage signature, displayed poor prognosis. On the 
other hand, several inhibitors of proteins involved in the DDR 
have been developed and some of them are either close to or 
are already being clinically trialed (20, 21). However, the effect 
of these types of compounds on MM cell viability has not been 
investigated in depth. In this study, we confirmed the presence of 
DSBs in several human myeloma cell lines (HMCLs) and evalu-
ated cell survival after inhibition of the DDR. Our results show 
that MM with ongoing endogenous DNA damage depends on 
ATR over ATM and on HR over NHEJ, providing evidence of the 
presence of RS in these cells. However, the absence of ATR was 
partially compensated by ATM, and NHEJ was activated when 
HR was inhibited before DNA resection. These findings suggest 
that multiple inhibition of the DDR or inhibition of HR after 
DNA resection could extend the therapeutic opportunities. The 
implications of our findings for the treatment of the disease are 
discussed.
MaTerials anD MeThODs
cells and culture conditions
The HMCL MM1S was acquired from American Type Culture 
Collection, and JJN3, RPMI-8226, U266, and OPM2 were 
obtained from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen. LINF903, an Epstein–Barr virus-transformed B-cell 
line established from a healthy individual, was obtained from the 
National DNA Bank of the University of Salamanca, Spain. MM 
and LINF903 cell lines were cultured in RPMI 1640–l-glutamine 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 10% of fetal bovine serum (Sigma-Aldrich) and antibiot-
ics (Gibco Life Technologies, Grand Island, NY, USA). All cells 
were incubated at 37°C in a 5% CO2 atmosphere. The presence of 
mycoplasma was routinely checked with a MycoAlert kit (Lonza, 
Basel, Switzerland) and only mycoplasma-free cells were used in 
the experiments.
immunofluorescence staining
Cells (50,000) were mounted on glass slides by cytospinning for 
10 min at 1,000 rpm. Cells were fixed in 2% paraformaldehyde for 
20 min, permeabilized in 0.2% Triton X-100 in PBS for 10 min, 
blocked in 3% BSA in PBS for 30 min and incubated with anti-
γ-H2AX (mouse, clone JBW301, Millipore) or anti-Rad51 (Ab-1, 
rabbit, Millipore) at 1:1,000 dilution for 2 h. After washing, slides 
were incubated with fluorescent secondary antibodies (1:1,000, 
Alexa Fluor 488 goat anti-mouse IgG or Alexa Fluor 568 anti-
rabbit) for 1 h. Slides were mounted with ProLong Gold antifade 
reagent (Invitrogen, Carlsbad, CA, USA), and images were 
acquired using a DeltaVision system made up of a Olympus IX71 
microscope, a Photometrics Coolsnap camera, and SOFWORX 
software. A 60× oil immersion objective was used.
immunoblotting
Cells were washed with PBS and resuspended in RIPA lysis 
buffer (Santa Cruz Biotechnology) containing protease inhibi-
tors (Complete, Roche Applied Science, Indianapolis, IN, USA) 
and phosphatase inhibitors (Santa Cruz Biotechnology). Protein 
concentration was measured using the Bradford assay (BioRad, 
FigUre 1 | several human myeloma cell lines exhibit a high level of endogenous Dna damage. (a) Percentage of cells with γH2AX or RAD51 foci  
in the indicated cell lines. Data are the mean of three independent experiments. At least 75 cells per experiment were counted. Error bars correspond to the SD 
(***p < 0.001 and **p < 0.01 compared with LINFB cells, Student’s t-test). (B) Representative immunofluorescence images of cells stained with anti-γH2AX or 
anti-RAD51 antibodies. (c) Western blot of kinase proteins involved in the DNA damage checkpoint.
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Hercules, CA, USA). Protein samples (20  μg/lane) were 
subjected to SDS-PAGE and transferred to PVDF membrane 
(BioRad). After blocking, membranes were incubated with 
anti-human antibodies. The following primary antibodies were 
used: anti-p-ATM (pSer1981, mouse, clone 10H11.E12, Santa Cruz 
Biotechnology), anti-ATM (rabbit, clone D2E2, Cell Signaling, 
Danvers, MA, USA), anti-p-ATR (Ser428, rabbit, Cell Signaling), 
anti-ATR (goat, Santa Cruz Biotechnology) anti-tubulin (rab-
bit, Abcam, Cambridge, UK). Horseradish peroxidase-linked 
donkey anti-rabbit, anti-mouse, or anti-goat antibodies (Santa 
Cruz Biotechnology) were used as secondary antibodies at 
1:10,000 dilution. Immunoblots were incubated for 1  h at RT 
and developed using enhanced chemiluminescence Western 
blotting detection reagents (Amersham Biosciences, Piscataway, 
NJ, USA).
reagents
KU-55933 and VE-821 were obtained from MedChemtronica 
(Stockholm, Sweden). Mirin was purchased from Sigma and 
NU7471 from Santa Cruz Biotechnology.
cell apoptosis assays
Apoptosis was measured using Annexin V–fluorescein isothio-
cyanate/propidium iodide (Annexin V-FITC/PI) double staining 
(Immunostep, Spain) according to the manufacturer’s guidelines.
cell cycle analysis
Cells were washed in PBS and fixed in 70% ethanol for later use. 
Cells were rehydrated with PBS, resuspended in 500  µl of PI/
RNase staining solution (Immunostep), and incubated for 20 min 
at RT in the dark. Samples were analyzed using a FACSCalibur 
flow cytometer.
hr Functional assay
To determine the in vivo levels of HR, a reporter plasmid (22) 
was integrated into the genome of JJN3 and U266 cell lines as 
follows: cell lines were transfected with 1 µg of the HR reporter 
plasmid linearized by digestion with NheI. Amaxa Cell Line 
Nucleofector Kit V and an Amaxa Nucleofector device (Lonza, 
Allendale, NJ, USA) were used with programs X-005, for the 
U266 cell line, and T-016 for the JJN3 cell line. Three days after 
transfection G418 was added at 500 µg/ml. Medium containing 
G418 was changed every 3 days. Stable pools were obtained after 
3 weeks of selection and were named U266-HR and JJN3-HR. 
In the chromosomally integrated reporter cassette, a unique 
DSB can be introduced by the rare-cutting endonuclease 
I-SceI. Upon induction of a DSB, a functional GFP gene can be 
reconstituted by gene conversion, the predominant HR repair 
pathway in mammalian cells (22). To evaluate HR efficiency, 
106 cells per transfection were cotransfected with 5  µg of an 
I-SceI-expressing plasmid together with 0.5 µg of pDsRed-N1 
FigUre 2 | continued
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FigUre 2 | continued  
Multiple myeloma cells with ongoing Dna damage are hypersensitive to the simultaneous inhibition of ataxia telangiectasia-mutated protein and 
ataxia telangiectasia and rad3-related protein kinases. (a) Cell survival after 48 h of treatment with 4 mM caffeine determined by Annexin V/propidium iodide 
(Annexin V/PI) staining. (B) Cell survival after 72 h in the absence (untreated = UT) or the presence of 10 µM KU-55933, 5 µM VE-821, or both. Cell viability in the 
absence of treatment (only DMSO) was taken as 100%, and values obtained for all other conditions were normalized with respect to the UT value. (c) Examples of 
flow cytometry dot plots of cells stained with Annexin V/PI after 72 h of treatment with the indicated chemical inhibitors. Data are the mean of at least three 
independent experiments (***p < 0.001, **p < 0.01, and *p < 0.05).
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to normalize measurements with respect to the transfection 
efficiency and were incubated in the presence or absence of 
various DDR inhibitors. Live cells were selected by FSC/SSC 
gating, and live GFP+ and DsRed+ cells were quantified by flow 
cytometry. HR efficiency was calculated as the ratio of GFP+ to 
DsRed+ cells.
resUlTs
hMcls exhibiting Dna Damage are 
hypersensitive to a combination of aTM 
and aTr inhibitors
Recent reports have shown ongoing constitutive DNA damage 
in several HMCLs and in plasma cells isolated from patients 
(6, 8). To corroborate these findings we quantified γ-H2AX and 
Rad51 foci, markers of DSBs, in HMCLs and in LINF903, a 
lymphoblastoid B cell line obtained from normal lymphocytes 
(7). HMCLs exhibited a higher percentage of cells with γ-H2AX 
and Rad51 foci than control lymphoblastoid cells, with the 
exception of U266 (Figures  1A,B), in agreement with recent 
published data (8). Activation of the DDR was detected in 
HMCLs with ongoing DNA damage by the presence of p-ATM 
and p-ATR (Figure 1C). The confirmation of high levels of DNA 
damage in most of the HMCLs prompted us to investigate the 
effect of various inhibitors of proteins involved in the DDR on 
MM cell viability. First, we analyzed the sensitivity of MM cell 
lines exhibiting low (U266) or high levels of DNA damage to 
caffeine, a well-known inhibitor of both ATM and ATR kinases. 
MM1S, RPMI-8226, and OPM2 were found to be more sensi-
tive to the drug than U266, as revealed by Annexin V-FITC/
PI staining (Figure  2A). Specific inhibitors were then used to 
determine whether cell death induced by caffeine in HMCLs 
was due to inhibition of ATM, ATR, or both kinases. Inhibition 
of ATM with 10 µM KU-55933 resulted in a small reduction in 
cell survival in U266 and MM1S cells relative to untreated cells, 
whereas no significant effect was detected in any other HMCLs 
(Figure 2B). On the other hand, pharmacological inhibition of 
ATR with 5 µM of the specific inhibitor VE-821 (23) triggered a 
stronger apoptotic response in MM1S, RPMI-8226, and OPM2 
than in LINF903 and U266 cell lines, in agreement with a recent 
report (8). Interestingly, inhibition of both kinases using a 
combination of the two drugs significantly increased cell death 
caused by ATR inhibition only in cells with high endogenous 
DNA damage (Figures 2B,C). These results indicated that ATM 
compensates for the absence of ATR, since the level of cell death 
caused by both inhibitors was higher than that observed with the 
individual inhibitors.
aTM and aTr Participate in DsB repair by 
hr in MM, and inhibition of Both Kinases 
Produces a stronger inhibitory effect
Ataxia telangiectasia-mutated protein and ATR kinases are mainly 
known for phosphorylating their substrates CHK2 and CHK1 
leading to cell cycle arrest in G1 or G2 (12, 24–26). However, 
even though many HMCLs exhibited endogenous DNA damage 
we found that cell cycle profiles did not change significantly after 
treatment with the combination of ATM and ATR checkpoint 
inhibitors (Figures  3A,B). This result suggests that ATM and 
ATR may carry out other functions in cells with DNA damage 
that make them dependent on the presence of both kinases. It 
has previously been shown that unrepaired DSBs can lead to cell 
death (27) and also that ATM is important for DSB repair by HR, 
since its downregulation reduces HR efficiency (14). Based on 
these findings, we hypothesized that inhibition of both kinases 
might strongly affect DSB repair by HR, leading to the death of 
MM cells with accumulated DNA damage. To analyze whether 
inhibition of ATM, ATR, or both caused defects in recombina-
tion, we took advantage of an HR substrate that was integrated 
within the chromatin of the MM cell lines JJN3 and U266. DSBs 
were then generated by transfection of the resulting JJN3-HR and 
U266-HR cells with an I-SceI endonuclease-expressing plasmid, 
and HR efficiency in the presence or absence of the kinase inhibi-
tors was estimated. We found that ATM inhibition by treatment 
with KU-55933 (10  µM) strongly reduced HR efficiency in 
JJN3-HR and U266-HR (Figures 3C,D), although cells were still 
able to perform HR to some extent. ATR inhibition by VE-821 
also resulted in a notable reduction in HR that was lower than that 
induced by ATM inhibition in JJN3-HR, but higher in U266-HR. 
A stronger suppressive effect on HR was observed when both 
kinases were simultaneously inactivated, indicating that ATM 
partially compensates for the lack of ATR and vice versa.
Total inhibition of recombination severely 
affects survival of MM cells with Ongoing 
Dna Damage
Based on the results reported above we speculated that sensitivity 
to ATR inhibition is caused by an additional role of this protein to 
that performed in DSB repair. Cell death induced by the chemi-
cal inhibition of both kinases could be caused by the individual 
effect of ATR inhibition along with the more marked decrease 
in HR capability. It has previously been shown that inhibition 
of ATR in conditions of RS leads to replication fork collapse 
and the accumulation of DSBs (28, 29), so we hypothesized 
that such accumulation, together with defects in DSB repair, 
might underlie hypersensitivity to ATR inhibition in MM. To 
FigUre 3 | inhibition of ataxia telangiectasia-mutated protein and ataxia telangiectasia and rad3-related protein does not affect cell cycle profiles 
of multiple myeloma cells but greatly reduces the efficiency of homologous recombination (hr) by gene conversion. (a) Cell cycle profiles of the 
indicated human myeloma cell lines untreated (UT) or treated with 10 µM KU-55933 and 5 µM VE-821. Cells were collected after 30 h of treatment and stained with 
propidium iodide. (B) Distribution of cells in G1, S, and G2/M phases of the cell cycle. (c) GFP+ and DsRed+ cells after 30 h of transfection with 5 µg of I-SceI 
endonuclease-expressing plasmid and 0.5 µg pf pDSRed2-N1. (D) HR efficiency was calculated as the ratio of GFP+ to DsRed+ cells. The ratio in UT cells was 
taken to be 100% and in all other situations calculated as the percentage of UT controls. Data are the mean of three independent experiments. Error bars represent 
the SD (***p < 0.001, **p < 0.01, and * p < 0.05).
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FigUre 4 | inhibition of ataxia telangiectasia and rad3-related protein results in the accumulation of Dna double-strand breaks. (a) γH2AX foci in 
untreated (UT) cells and after 48 h of treatment with 5 µM VE-821. (B) Quantification of cells with foci. A total of 100 cells per cell line and condition were counted. 
Data are the mean of three independent experiments. Error bars represent the SD (**p < 0.01 compared with UT cells).
7
Herrero and Gutiérrez Addiction to DSB Repair by HR in MM
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 98
explore this possibility, cells were treated with VE-821, and the 
presence of DSBs was analyzed by monitoring γH2AX foci. As 
shown in Figures  4A,B, treatment of MM cells with VE-821 
clearly increased the number of cells with γH2AX foci relative to 
untreated controls. Number of γH2AX foci per cell also increased 
and in several cells became uncountable.
To explore whether the strong inhibition of HR causes the 
death of MM cells with ongoing DNA damage we used mirin, an 
MRE11 inhibitor that abolishes HR by impeding DSB resection 
(30). We also explored the contribution of the other main path-
way involved in DSB repair, NHEJ, to the survival of MM cells 
exhibiting DNA damage. For this purpose, we used NU7441, 
a NHEJ inhibitor that targets DNA-PK (31). We found that 
treatment for 72 h with mirin reduced survival of MM1S, RPMI-
8226, and JJN3 in a dose-dependent manner, whereas survival 
of LIN903 and U266 cells was higher, as expected, and remained 
similar at the different doses of mirin employed (Figures 4A,B). 
On the other hand, inhibition of NHEJ with concentrations of 
NU7441 up to 40 µM did not affect survival of any of the cell 
lines analyzed, but clearly decreased survival of HMCLs with a 
high level of ongoing DNA damage when treated with 25 and 
50 µM mirin. Based on these results we concluded that mirin 
at 25 or 50  µM might not completely inhibit HR, and, if so, 
cells might survive HR inhibition by the compensatory NHEJ 
pathway. To explore this hypothesis, JJN3-HR and U266-HR 
cells carrying the HR reported cassette were treated with dif-
ferent doses of mirin, and HR efficiency was analyzed after 
30 h of culture (Figure 5C). We found that the recombination 
efficiency of live cells decreased with increasing doses of mirin, 
from a partial loss of efficiency at 25 µM to a nearly total loss 
at 100 µM. These results indicated that HMCLs with ongoing 
DNA damage are hypersensitive to HR inhibition and also that 
defects in DNA resection induced by mirin can be compensated 
by NHEJ, a mechanism able to rejoin broken molecules before 
total resection occurs (32). Importantly, the reduction in HR 
was very similar in JJN3-HR and U266-HR (Figure 5C), which 
demonstrated that U266 was more resistant to mirin because it 
suffered less endogenous DNA damage, and not because mirin 
was not active in these cells.
To confirm the dependency of MM cells on HR we used B02, 
a recently discovered inhibitor of Rad51 (33). HMCLs were treated 
with different doses of B02, and HR efficiency and cell viability were 
analyzed. As expected, B02 clearly inhibited HR in both U266-HR 
and JJN3-HR reporter cell lines (Figure 6A), although inhibition 
of HR resulted in more cell death in JJN3 and RPMI-8226 than 
in U266 (Figures 6B,C), further confirming that MM cells with 
ongoing DNA damage are hypersensitive to HR inhibition. We 
found that simultaneous inhibition of HR using B02 and NHEJ 
with NU7441 did not increase cell death induced by B02 alone 
(Figure 6B). This result clearly indicated that endogenous DNA 
damage in MM is mainly repaired by HR and that if this pathway 
is inhibited after DNA resection occurs the break can no longer 
be repaired by a compensatory NHEJ mechanism. An illustration 
summarizing all the results is shown in Figure 7.
DiscUssiOn
High levels of DNA damage can make tumor cells dependent on 
a proper DDR and represent a vulnerability of cancer cells that 
could be targeted therapeutically (34). In this study, we show that 
inhibition of the DDR is particularly toxic for MM cells exhibit-
ing high levels of DSBs. Specifically, MM cells were found to be 
hypersensitive to agents that inhibit DSB repair by HR, a pathway 
upregulated in MM and important for the resolution of breaks 
associated with RS.
Recently, Cottini et al. showed that several HMCLs suffer RS, 
which is induced, at least in part, by the overexpression of MYC. 
In fact, silencing this oncogene in HMCLs exhibiting DNA dam-
age and MYC overexpression reduced the number of lesions. On 
the other hand, its overexpression in U266, an HMCL with low 
levels of DNA damage and no MYC overexpression, triggered 
an increase in DSBs (8). The authors also found that ATR, the 
main kinase involved in the RS response, promoted survival of 
MYC-overexpressing cells. Here, we confirm the presence of high 
levels of DNA damage in several HMCLs, with the exception of 
U266, whose level of endogenous DNA damage was similar to 
that found in normal lymphoblastoid B cells, which were used 
in this work as healthy controls. We also confirmed that HMCLs 
FigUre 5 | Mirin induces cell death of multiple myeloma cells with endogenous Dna damage and reduces homologous recombination (hr) 
efficiency in a dose-dependent manner. (a) Cell survival determined by Annexin/propidium iodide (Annexin/PI) staining after 72 h of treatment with the indicated 
compounds. (B) Representative flow cytometry dot plots of cells stained with Annexin/PI. (c) HR efficiency in the indicated conditions. Data are the mean of three 
independent experiments. Error bars correspond to the SD (***p < 0.001 and *p < 0.05).
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FigUre 6 | B02 reduces homologous recombination (hr) efficiency and induces multiple myeloma cell death. (a) Efficiency of HR after treatment with 
B02. (B) Cell survival determined by Annexin–fluorescein isothiocyanate/propidium iodide staining of human myeloma cell lines (HMCLs) treated for 72 h with the 
indicated inhibitors. A total of 10,000 events are shown. (c) Representative dot plots of the indicated HMCLs. Data are the mean of three independent experiments. 
Error bars represent the SD (***p < 0.001).
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exhibiting DNA damage rely on activated ATR for survival. 
Moreover, we observed that these cells were more sensitive to 
ATR than to ATM inhibition, probably because the first induces 
replication fork collapse (28, 29), leading to the accumulation 
of DSBs (Figure  4). However, we found that the absence of 
ATR was compensated by ATM, since cell death induced by the 
inhibition of both kinases was more extensive than that obtained 
using single kinase inhibitors. It is especially noteworthy that 
the lethal effects of ATM and ATR inhibitors were found only in 
cells with extensive endogenous DNA damage, which bolsters 
the therapeutic opportunities. ATR and ATM transduction 
pathways were initially considered as two parallel pathways: 
IR induced the ATM pathway, whereas RS activated the ATR 
pathway. However, the regulation of ATM and ATR was later 
FigUre 7 | several multiple myeloma patients present Pcs with high 
levels of replication stress (rs), leading to double-strand breaks 
(DsBs). These cells activate the DNA damage response that coordinates the 
signaling and the repair of the lesions. Replication-associated DSBs are 
mainly repaired by homologous recombination (HR). Targeting HR by dual 
inhibition of ataxia telangiectasia-mutated protein and ataxia telangiectasia 
and Rad3-related protein or by using the HR inhibitor B02 would be 
particularly toxic for these cells. High levels of cell death will also be achieved 
using mirin and NU7471, since the last inhibits the compensatory non-
homologous end joining mechanisms. In contrast, normal cells with minimal 
levels of RS are expected to survive these treatments.
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shown to be mutually dependent in response to various DNA-
damaging conditions like UV light, IR, and replication stalling 
(35–39). Thus, ATM has been demonstrated to play a role in 
maintaining fragile site stability, which is revealed only in the 
absence of ATR (40). Our results showing an increase in MM cell 
death with the combination of the two kinase inhibitors indicate 
the importance of both proteins for coping with endogenous 
DNA damage in MM and suggest that a double therapy could 
be more efficient for killing malignant cells. In this regard, it 
has been reported that in ATM-defective chronic lymphocytic 
leukemia cells, inhibition of ATR signaling by AZD6738 leads to 
an accumulation of unrepaired DNA damage that results in cell 
death by mitotic catastrophe (41). Dual inhibition of ATR and 
ATM has also been shown to potentiate the activity of the DSB-
inducing drugs trabectedin and lurbinectedin by perturbing the 
DDR and HR repair (42).
We show for the first time that ATM and ATR are involved in 
DSB repair by HR in MM and also that inhibition of both kinases 
completely abolishes HR efficiency. These results, obtained using 
an integrated-GFP-based DNA repair reporter substrate, support 
a previously described model in which ATM and ATR collaborate 
to maintain the activity of CtIP for efficient DNA end resection 
during HR (43). We found that ATM/ATR inhibition did not 
affect cell cycle distribution of HMCLs with high endogenous 
DNA damage (Figures 3A,B), which led us to hypothesize that 
the effect on HR, together with the accumulation of DSBs due 
to ATR inhibition, might underlie cell death induction. This 
hypothesis was supported by the finding that abolition of HR 
using the MRE11 inhibitor mirin, or the RAD51 inhibitor B02, 
severely decreased survival of HMCLs exhibiting high levels of 
endogenous DNA damage. Here, we show that inhibition of the 
other route involved in DSB repair, NHEJ, using the DNA-PK 
inhibitor NU7441 did not affect MM cell viability, which clearly 
demonstrated that endogenous DNA damage in MM is repaired 
by HR. We found that NHEJ inhibition did not increase cell death 
when HR was simultaneously inhibited with B02, but did clearly 
enhance cell death when HR was inhibited with mirin, which 
interferes with recombination before DNA resection occurs. 
These results are consistent with previous observations by Shibata 
et  al., who showed that inhibition of the endonuclease activity 
of MRE11 promoted NHEJ (32). They are also consistent with 
the notion that 3′-ssDNA ends generated after DNA resection 
as substrates for HR can no longer be channeled toward NHEJ 
(18). Importantly, our results indicate that inhibition of HR after 
the initial step of end resection might be more appropriate for 
inducing MM cell death, since it prevents the occurrence of a 
compensatory NHEJ repair mechanism.
Many studies have shown that combinations of genotoxic 
agents with inhibitors of the DDR produce greater cell death of 
tumor cells compared with single agents (21, 44–46). In MM, the 
cytotoxic effects of bendamustine, melphalan, and doxorubicin 
on p53-deficient cells are enhanced by AZD7762, a CHK1/CHK2 
inhibitor (47). In addition, inhibition of RAD51 has been found 
to sensitize MM cells to IR and to the DSB-inducing drug doxo-
rubicin (48). However, the present study is the first to indicate 
that the single-agent activity of HR inhibitors induces apoptosis 
of MM cells with intrinsic DNA damage, providing a therapeutic 
window. It is important to note that partial inhibition of HR did 
not result in complete myeloma cell death at the times assayed, 
probably because residual traces of activity may be enough to 
ensure repair of endogenous DSBs. However, doses that com-
pletely abolished HR, such as the combination of ATM and ATR 
inhibitors, or concentrations of B02 greater than 15  µM drove 
most of the MM cells with intrinsic DNA damage to apoptosis. It 
is possible that the high doses of HR inhibitors needed to induce 
complete MM cell death could have a toxic effect, especially 
over prolonged periods, but maybe one that is less severe than 
that induced by combinations of DDR inhibitors with genotoxic 
agents, since the latter induce DNA damage and are also toxic to 
non-tumor cells. Nevertheless, specific (or temporary) inhibition 
of HR could be efficient not only for reducing MM cell survival 
but also for mitigating genomic instability and disease progres-
sion, given that we and others have demonstrated a high level 
of RAD51 expression and increased HR that lead to the genome 
instability characteristic of the disease (5, 7). Taken together, our 
findings suggest that HR inhibition could be a promising target 
for the treatment of MM. Therapeutic outcomes and toxicity 
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profiles of the different inhibitors used as single agents or in 
combinations need to be tested in clinical trials.
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